



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61B 8/00	A1	(11) International Publication Number: WO 00/57792 (43) International Publication Date: 05 October 2000 (05.10.2000)
(21) International Application Number: PCT/US00/08259 (22) International Filing Date: 28 March 2000 (28.03.2000) (30) Priority Data: 09/282,514 31 March 1999 (31.03.1999) US (60) Parent Application or Grant POINT BIOMEDICAL CORPORATION [/]; O. TICKNER, E., Glenn [/]; O. CONSTON, Stanley, R. [/]; O. TICKNER, E., Glenn [/]; O. CONSTON, Stanley, R. [/]; O. SUYAT, Reginald, J. ; O.	Published	
(54) Title: A METHOD TO MEASURE AMBIENT FLUID PRESSURE (54) Titre: PROCEDE DE MESURE DE LA PRESSION DE FLUIDE AMBIANTE		
(57) Abstract <p>A method is provided for measuring real time ambient pressure at a region of interest in a fluid-filled body cavity by introducing into the cavity a composition of gas-containing micro-bubbles having a predetermined fragility threshold correlating to the rupture response of their capsules to the ambient fluid pressure, and/or applied acoustic pressure. An ultrasonic signal is applied at the region of interest at a power level sufficient to destroy the micro-bubble population having a fragility threshold below the applied power level. The ultrasound backscatter response (AD) is detected from the population of intact, the disintegrating micro-bubbles remaining at the region of interest, and this backscatter signal is correlated to predetermined acoustic response properties to determine the ambient pressure (mm Hg) at the region of interest.</p> (57) Abrégé <p>L'invention concerne un procédé destiné à mesurer la pression ambiante en temps réel dans une zone d'intérêt à l'intérieur d'une cavité du corps remplie de fluide, selon lequel on introduit dans ladite cavité une composition de gaz contenant des microbulles ayant un seuil de fragilité prédéterminé mettant en corrélation la rupture de la capsule des microbulles avec la pression ambiante du fluide et/ou de la pression acoustique appliquée. Un signal ultrasonore est appliqué à la zone d'intérêt à un niveau de puissance suffisant pour détruire la population de microbulles ayant un seuil de fragilité inférieur au niveau de puissance appliqué. La réponse de rétrodiffusion ultrasonore (AD) est détectée parmi la population de microbulles intactes et en voie de désintégration demeurant dans la zone d'intérêt. Ce signal de rétrodiffusion est mis en rapport avec des propriétés de réponse acoustique prédéterminées afin de déterminer la pression ambiante (mm Hg) dans la zone d'intérêt.</p>		

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61B 8/00		A1	(11) International Publication Number: WO 00/57792 (43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: PCT/US00/08259 (22) International Filing Date: 28 March 2000 (28.03.00) (30) Priority Data: 09/282,514 31 March 1999 (31.03.99) US (71) Applicant (for all designated States except US): POINT BIOMEDICAL CORPORATION [US/US]; 887A Industrial Road, San Carlos, CA 94070 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TICKNER, E., Glenn [US/US]; 859 University Avenue #1, Los Gatos, CA 95030 (US). CONSTON, Stanley, R. [US/US]; 148 Rogers Avenue, San Carlos, CA 94070 (US). (74) Agent: SUYAT, Reginald, J.; Fish & Richardson P.C., Suite 100, 2200 Sand Hill Road, Menlo Park, CA 94025 (US).			(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.

(54) Title: A METHOD TO MEASURE AMBIENT FLUID PRESSURE



(57) Abstract

A method is provided for measuring real time ambient pressure at a region of interest in a fluid-filled body cavity by introducing into the cavity a composition of gas-containing micro-bubbles having a predetermined fragility threshold correlating to the rupture response of their capsules to the ambient fluid pressure, and/or applied acoustic pressure. An ultrasonic signal is applied at the region of interest at a power level sufficient to destroy the micro-bubble population having a fragility threshold below the applied power level. The ultrasound backscatter response (AD) is detected from the population of intact, the disintegrating micro-bubbles remaining at the region of interest, and this backscatter signal is correlated to predetermined acoustic response properties to determine the ambient pressure (mm Hg) at the region of interest.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

A METHOD TO MEASURE AMBIENT FLUID PRESSURE

10

5

The present invention relates to a method for measuring real time ambient fluid pressure within a fluid-filled body cavity using gas-filled microbubbles and ultrasonic acoustic energy.

15

Background of Invention

20

10

Typically, cardiovascular pressures are measured using catheters which are introduced into the vascular systems via an artery or vein. Catheters exhibit a finite risk of both morbidity and mortality with routine usage in the clinical situation. More recently, sensor tipped guidewires to measure pressure have been developed. However, this procedure is also invasive with concomitant associations of morbidity and mortality.

25

15

There are currently no adequately accurate direct, noninvasive real time clinical methods used to measure pressure in the cardiovascular system. An indirect method exists using Doppler ultrasound as suggested by Laaban, et al. (Laaban, J., Diebold, B., Zelinski, R., Lafay, M., Raffoul, H., and Rochemaure, J., *Chest* 96, (6): 1258-1262, 1989). With Doppler techniques, blood flow velocities are measured using ultrasonic scanners

30

35

20

operating in the Doppler mode. By applying the Bernoulli equation and knowing the peak velocity, it is possible to calculate the pressure drop across a cardiac valve that created the flow. If one starts measurements in a vein such as the superior vena cava of known low pressure, one can calculate the pressure in the right ventricle and pulmonary artery and even make an estimate of the endiastolic left ventricular pressure with the technique. The indirect approach is filled with errors in difficult cases when good data is most needed and is used only for diagnosing the right side of the heart. Other non-invasive measurement

40

45

25

50

55

5 schemes have been proposed (Blazek; Vladimir, Schmitt; Hans-J., U.S. Patent No.
5,447,161; Aakhus, S., Soerlie, C., Faanes, A., Hauger, S. O., Bjoemstad, K., Hatle, L.,
and Angelsen, B. A. J., *American Journal of Cardiology*, 72: 260-267, 1993; Kyriakides,
10 Z. S., Kremastinos, D. T., Rentoukas, E., Vavelidis, J., Damianou, C., and Toutouzas, P.,
5 *International Journal of Cardiology*, 33: 267-274, 1991; Neuman, A., Soble, J. S.,
Anagnos, P. C., Kagzi, M., and Parrillo, J. E., *Journal of the American Society of*
15 *Echocardiography*, 11(2): 126-131, 1998) but show no significant advancement to the
field.

20 In U.S. Patent No. 3,640,271 to Horton, there is presented the concept of injecting
10 a single bubble of known size into a patient for the purpose of measuring blood pressure.
The concept was to stimulate the bubble into resonance ultrasonically and from the
25 received backscattered signal, determine the resonant frequency of the bubble. It is further
known that if both the diameter of the bubble and the resonant frequency are known, then
30 the unknown pressure could be calculated. However, it is not known that the precision
15 sized bubbles required for the technical approach have ever been achieved. Also, at
present, it would be nearly impossible to locate bubbles within a specific organ or cavity
35 for the very low concentration of bubbles required by the technology.

In Patent No. 4,265,251 to Tickner, the concept of encapsulating a pressurized
bubble within a fused saccharide shell is presented. The shell begins to dissolve in the
40 20 circulatory system, thinning the wall. At some point in its dissolution, the shell fractures
and the bubble escapes and expands. In so doing, it over-expands from its encapsulated
45 diameter which sets it to free-ringing. A passive external transducer detects the free
ringing signals and, by applying the same equations identified by Horton, computes the
pressure. A limitation to the technology for usable clinical practice is the inability to
50

5 control the point of rupture and the lack of precision (Osterle S., Sahines, T., Tucker, C.,
Tickner, E., et al., *The Western Journal of Medicine*, 1985 Ott; 143: 463-468.

10 In U.S. Patent No. 5,749,364 to Sliwa, the concept for mapping cardiac pressures
is presented by injecting a population of non-precision microspheres into the blood pool.
5 Theory indicates that the resonant frequency peak of an encapsulated bubble is
mathematically related to the ambient pressure. By examining the backscattered signal of
15 the microspheres and from the change in their frequency spectrum, a map of the pressure
in at least two dimensions is derived. One claimed method for doing this is to inject two
20 microsphere population types, which exhibit different backscatter characteristics, and then
10 use these different characteristics to deduce ambient pressures. Other work in using
frequency shift has been explored. However, no clinical applications are known to have
25 been developed (Ishihara, K., Kitabatake, A., Tanouchi, J., Fujii, K., Uematsu, M.,
Yoshida, Y., Kamada, T., Tamura, T., Chihara, K., and Shirae, K., *Jpn. J. Appl. Phys.*,
30 27(Suppl 27-1): 125-127, 1988) possibly due to the difficulties in measuring *in-vivo*
15 frequency shifts. Furthermore, commercial ultrasound scanners have relatively narrow
frequency bandwidths, which would not allow for the frequency range scan needed to
35 detect changes in resonant frequency, especially in a formulation with multiple
microsphere populations with attendant multiple resonance peaks.

40 In PCT No. 98/32378 (De Jong, N., Frinking, P., PCT No. WO 98/32378, July 30,
20 1998; Bouakaz, A., Frinking, P., De Jong, N., Non-Invasive Pressure Measurement in a
Fluid Filled Cavity, *Abstract: The Fourth Heart Centre Symposium on Ultrasound*
45 *Contrast Imaging*, Jan. 21-22, 1999) there is disclosed the use of the decay of free gas
bubbles to measure ambient pressure or temperature. The decay time of the gas bubble is
50 dependent on the gas type, the liquid characteristics, the solubility of the gas within the

liquid, the excitation frequency and the ambient temperature and pressure. However, in their scheme the microsphere is used only as a transport mechanism which releases the free bubble upon insonation and the properties of the free bubble are utilized for pressure measurement. They propose using a series of intermittent high power pulses to break the capsule of the microsphere, releasing the gas bubble and then using a series of intermittent low power pulses to determine the decay time of the bubble and therefore calculate pressure or temperature. Although the mechanism described uses a power level to rupture the capsule that is above a threshold, the fragility or release mechanism of the microsphere capsule itself is not controlled. Furthermore, if the microsphere has a very weak capsule, breakage of the capsule can occur at very low ultrasound powers. This leads to a response which is not controlled relative to imaging depth and applied power.

Summary of the Invention

The present invention is directed to a method for measuring real time pressure in a region of interest in a fluid-filled body cavity. A composition of gas-containing microbubbles is introduced into the cavity, the microbubbles having a predetermined fragility threshold where the fragility threshold is correlated with the rupture response to fluid pressure, applied acoustic pressure, or a combination of both fluid and applied acoustic pressures. The acoustic pressure is applied from an ultrasonic energy producing source. The composition of microbubbles has predetermined acoustic response properties correlating to ambient pressure of the surrounding fluid. When the microbubbles are at the region of interest, an ultrasonic signal is applied at a power level sufficient to cause acoustic pressure sufficient to destroy or disrupt the membrane of the encapsulated microbubble population having a fragility threshold below the applied power level. Then,

the ultrasound backscatter response is detected from the population of intact and failing microbubbles remaining at the region of interest and the backscatter signals are correlated to the predetermined acoustic response properties of the microbubble composition to determine the ambient pressure at the region of interest.

Brief Description of the Drawings

Fig. 1 is a plot of average acoustic density versus ambient fluid pressure of microbubbles tested in Example 1;

Fig. 2 is a plot of power Doppler plume length versus ambient fluid pressure of the test on microbubbles tested in Example 2;

Fig. 3 is a plot of mean acoustic density versus distance, defining the fragility slope of the microbubbles tested in Example 4;

Fig. 4 is a plot of the fragility slopes of three microbubble compositions versus mechanical index as described in Example 4 to define the fragility curve;

Fig. 5 is a graph showing the fragility thresholds of three different microbubble compositions having three different wall thickness;

Fig. 6 is a plot of the backscatter signal versus mechanical index at three different pressures of a microbubble composition having 110nm wall thickness;

Fig. 7 is a plot of fragility slopes versus mechanical index of a microbubble composition having 110nm wall thickness at three different pressures;

Fig. 8 is a plot of the fragility slope intercept versus pressure from the data shown in Fig. 7.

Description of the Preferred Embodiments

As used herein the term microbubbles is intended to include microspheres,

5 microcapsules and microparticles which are hollow and enclosing a core which may be
filled with a gas. This may be a matrix material. It is not necessary for the microbubbles
to be precisely spherical although they generally will be spherical and described as having
10 average diameters. If the microbubbles are not spherical, then the diameters are referred
to or linked to the diameter of a corresponding spherical microparticle having the same
mass and enclosing approximately the same volume of interior space as a non-spherical
15 microbubble. Microbubbles may be comprised of surface tension stabilized gas bubbles,
surfactant stabilized gas bubbles, lipids and liposomes, synthetic polymers and biopolymers;
and may further comprise one or more layers of suitable material.

10 Ultrasonic backscatter of gas filled microbubbles and bubble resonance are well
known in the ultrasound contrast field. It is known from the bubble resonance equations
25 that resonant frequency and pressure are mathematically related. Theory indicates that an
encapsulated gas bubble under insonation has a spectral envelope with a pronounced peak
value at microbubble resonance and this aspect leads to the prior art methods of using
30 resonant frequency shifts to determine pressure. However, in simulations with
commercially available microbubble contrast agents, a nearly flat frequency response has
15 been measured and reported by Boualaz, et al., (Bouakaz, A., DeJong, N., Cachard, C.,
and Jouini, K., *Ultrasonics* 36: 703-708, 1998). Thus, using frequency shift, it may be
difficult to estimate in-vivo pressure.

20 To overcome the microbubble resonance detection problem, this invention focuses
on the encapsulated bubble property of capsule fragility. The capsule of a microbubble can
structurally fail from both static and dynamic pressure or combinations of the two. The
45 ultrasonic waves can then disrupt or disintegrate the freed/escaping gas bubbles sufficiently
to decrease their backscattering cross-section.

5 The intensity of backscattered signals depends upon the number of bubbles present
in the sample volume and the size of the bubbles. If the size of the microbubble population
is constant, then if capsules are broken for any reason and the encapsulated gas within
10 dissolves or disintegrates into smaller bubbles, there is a concomitant decrease in
5 backscattered signal intensity.

15 In the case of a gas filled microbubble used in the method of the present invention,
the materials of the capsule wall, and the properties of those materials are selected and
prepared to allow for the rupture of the capsule at critical or threshold pressures or within
20 defined pressure limits. The microbubbles prepared in this manner are referred to herein as
10 having engineered fragility. By fabricating a microbubble agent with a specifically
designed fragility response and by controlling the applied ultrasound power, one can
25 selectively rupture a gas containing microbubble, releasing the gas bubble, which then
dissolves or breaks up under insonation in the ambient fluid. Since backscatter depends
30 upon the presence of gas bubbles or gas containing microbubbles and their ability to re-
15 radiate incident signals, backscatter signal intensity is decreased when the population of
microbubbles or free bubbles decreases or the diameter of the bubbles decreases.

35 However, in order to alter the backscatter on a clinically useable timescale, it becomes
necessary to both structurally fail the capsule wall and have the released gas bubble
dissolve or disintegrate quickly in the blood stream. The method herein disclosed takes
40 20 advantage of this process by using the decrease in signal intensity and/or amplitude as a
means of identifying the unknown pressure, instead of the shift in resonant frequency or
45 decay time of a free gas bubble. Since microbubbles can be seen within cardiac chambers
and even destroyed by ultrasonic imaging scanners, the present invention provides a viable
50 way for measuring pressure in real time provided that the microbubbles are designed and

5 fabricated to meet certain specifications. These specifications concern the relationship
between static and dynamic stresses within the membrane or capsule shell that when
exceeded cause structural failure. The released free gas bubble should quickly dissolve or
10 disintegrate into much smaller bubbles so as not to continue to backscatter incident
5 signals.

15 Accordingly, having prepared microbubble compositions with engineered fragility,
such compositions are used to measure the real time ambient fluid pressure at a region of
interest in a fluid-filled cavity, such as the heart. Typically the microbubble composition
20 will be introduced into the blood system and the location of the composition within the
10 body can be monitored by conventional ultrasound scanning. At the region of interest,
acoustic pressure can be applied by a focused ultrasound source to rupture the capsules of
25 the microbubbles which have a fragility threshold below the power level of the applied
acoustic pressure. Then the ultrasound backscatter response from the remaining
30 population of intact microbubbles or disintegrating gas bubbles at the region of interest is
15 made and correlated to predetermined acoustic response properties of the microbubble
composition to determine the ambient pressure at the region of interest. The results may
35 be displayed as a qualitative or quantitative pressure map using greyscale or color overlays
of the base image.

40 In general, the ambient pressure at a region of interest can be determined by
20 correlating pressure to the acoustic energy required to rupture the capsule of the
microbubbles. First, a predetermined correlation of acoustic energy, typically given as a
45 mechanical index, to pressure is made. This may be experimentally determined by
measuring the microbubble response under pressure at an acoustically targeted site.
Fragility slopes of various populations may then be experimentally determined from the
50

5 results of acoustic density vs. distance along a channel containing an acoustically
interrogated population of flowing microbubbles. The fragility slopes are then plotted to
derive fragility curves of fragility slope vs. mechanical index. There are substantially linear
10 portions of each fragility curve which, when extended to the intercept at the zero fragility
slope value, determine the mechanical index at the threshold fragility. This mechanical
index correlates to the threshold fragility when the microbubbles rupture, and is dependent
15 upon the ambient fluid pressure.

This can be accomplished by several methods. Since the microbubble formulations
can be made with uniform properties, a fragility versus pressure characteristic of the
20 composition may be predetermined by in vitro experiments to develop a response curve.
In one such method when the composition is injected into the bloodstream, a focused
25 ultrasound scanner is applied at a low power sound pulse or pulse train to establish a
baseline. Then a second pulse or pulse train is applied at a higher power which is selected
to destroy the segment of the microbubble population whose fragility threshold is below
30 the power level of the second pulse. A third pulse or pulse train also at high power is then
used to measure the post destruction backscatter response. The difference of the
35 backscatter signal from the third pulse versus the baseline is a measure of the pressure in
the ambient fluid and can be determined by reference to the response curve. The results
may be displayed on the monitor of the ultrasound scanner as a real time overlay, either in
40 greyscale or color.

20
Another method of utilizing the microbubbles to measure ambient pressure is to
45 combine a microbubble composition fabricated from two or more populations of gas-filled
microbubbles where each population comprises differing fragility thresholds. The fragility
versus pressure characteristics of each population as well as the combined population are
50

predetermined by in vitro experiments and the response curve is developed. After
administering the formulation into the bloodstream by bolus injection or infusion, an
ultrasound scanner is focused on the region of interest to apply successively increasing
power pulses or pulse trains. At each power setting, that population of microbubbles
whose fragility threshold is below the power level of the pulse will be destroyed. The
decay in the intensity of the backscatter signal from each successive pulse is a measure of
the pressure in the ambient fluid. The pressure measurement is calculated from this decay,
referenced to the known response curve, and is displayed on the monitor.

Yet another method is to inject a single population of microbubbles having a
population with a fragility threshold that is linearly decreasing with increasing ambient
pressure and under constant applied ultrasound pressure. The fragility curve is determined
by empirical analysis. An ultrasound scan of the cardiac chambers, for example, may be
performed under a power Doppler mode at a constant power level so that the quantity of
microbubble destruction within the chambers will be dependent upon the ambient pressure.
Each destruction event of a microbubble will result in a decorrelation signal being detected
and displayed by the ultrasound scanner. The intensity of the Power Doppler ultrasound
display will be directly proportional to the ambient fluid pressure, by way of the
predetermined response.

By yet another method, the pressure in the chamber of the heart or across a heart
valve may be measured. The acoustic density value of a series of adjacent regions of
interest are measured along a scanline axis of the ultrasound transducer a rapid sequence.
The slope of a plot of the acoustical density versus distance along the scanline axis is
determined and compared to predetermined values of the acoustical density versus
pressure. The data can then be displayed as a pressure value along the scanline. By

5 repeating the determination as subsequent scanlines, the pressure value for a region within the chamber can be determined and displayed.

10 An alternate method to measure pressure is as follows. A region of interest containing microbubbles of engineered fragility is interrogated with a series of ultrasound pulses in rapid succession of steadily increasing power values: $P_1, P_2, \dots P_n$, and respective acoustic density or backscatter signal levels are determined: $B_1, B_2, \dots B_n$. A fragility curve, as shown in Example 4 below, made by plotting the slope (taken from the results of 15 acoustical density versus distance) versus mechanical index, is computed to determine the pressure from either the slope of the fragility curve which occurs in a nearly linear high power region or from a computed zero slope intercept as shown in Example 4 below. Comparing the data to a predetermined table of correlation to pressure will show pressure 20 at the point of measurement. Real time display of the pressure can then be accomplished by the ultrasound scanner.

30 The microbubbles according to the present invention may be a surface tension or surfactant stabilized gas bubble or have a mono-layer shell but preferably have at least a bi-layered shell. The outer layer of the shell will be a biologically compatible material or biomaterial since it defines the surface which will be exposed to the blood and tissues 35 within the body. The inner layer of the shell will be a biodegradable polymer, which may be a synthetic polymer, which may be tailored to provide the desired mechanical and acoustic properties to the shell. The cores of the microbubbles contain gas, typically air, 40 nitrogen or a fluorocarbon gas. To make the microbubbles rupturable by ultrasound energy, they must contain a gas to allow acoustic coupling and particle oscillation. Microbubbles are constructed such that the majority of those prepared in a composition 45 will have diameters within the range of about one to ten microns in order to pass through

the capillary system of the body.

Since the microbubbles preferably have an outer and inner layer, the layers can be tailored to serve different functions. The outer shell which is exposed to the blood and tissues serves as the biological interface between the microbubbles and the body. Thus it will be made of a biocompatible material which is typically amphiphilic, that is, has both hydrophobic and hydrophilic characteristics. Blood compatible materials are particularly preferred. Such preferred materials are biological materials including proteins such as collagen, gelatin or serum albumins or globulins, either derived from humans or having a structure similar to the human protein, glycosaminoglycans such as hyaluronic acid, heparin and chondroitin sulphate and combinations or derivatives thereof. Synthetic biodegradable polymers, such as polyethylene glycol, polyethylene oxide, polypropylene glycol and combinations or derivatives may also be used. The outer layer typically has a chemistry which allows charge and chemical modification. The versatility of the surface allows for such modifications as altering the charge of the outer shell, such as by selecting a type A gelatin having an isoelectric point above physiological pH, or by using a type B gelatin having an isoelectric point below physiological pH. The outer surfaces may also be chemically modified to enhance biocompatibility, such as by PEGylation, succinylation or amidation, as well chemically binding to the surface a targeting moiety for binding to selected tissues. The targeting moieties may be antibodies, cell receptors, lectins, selectins, integrins or chemical structures or analogues of the receptor targets of such materials. The mechanical properties of the outer layer may also be modified, such as by cross linking, to make the microbubbles suitable for passage to the left ventricle.

The inner shell will be a biodegradable polymer, which may be a synthetic polymer. An advantage of the inner shell is that it provides additional mechanical properties to the

microbubble which are not provided or insufficiently provided by the outer layer or, enhances mechanical properties not sufficiently provided by the outer layer, without being constrained by surface property requirements. For example, a biocompatible outer layer of a cross-linked proteinaceous hydrogel can be physically supported using a high moduli synthetic polymer as the inner layer. The polymer may be selected for its modulus of elasticity and elongation, which define the desired mechanical properties. Typical biodegradable polymers include polycaprolactone, polylactic acid, polylactic-polyglycolic acid co-polymers, co-polymers of lactides and lactones, such as epsilon-caprolactone, delta-valerolactone, polyalkylcyanoacrylates, polyamides, polyhydroxybutyrates, polydioxanones, poly-beta-aminoketones, polyanhydrides, poly-(ortho)esters, polyamino acids, such as polyglutamic and polyaspartic acids or esters of polyglutamic and polyaspartic acids. References on many biodegradable polymers are cited in Langer, et. al. (1983) *Macromol.Chem.Phys.* C23, 61-125.

The inner layer permits the modification of the mechanical properties of the shell of the microbubble which are not provided by the outer layer alone. For use as an ultrasonic contrast agent, the inner layer will typically have thickness which is no larger than is necessary to meet the minimum mechanical requirements, in order to maximize the interior gas volume of the microbubble. The greater the gas volume within the microbubble the better the echogenic properties.

The combined thickness of the outer and inner layers of the microbubble shell will depend in part on the mechanical properties required of the microbubble, but typically the total shell thickness will be in the range of 25 to 750 nm.

The microbubbles may be prepared by an emulsification process to control the sequential interfacial deposition of shell materials. Due to the amphiphilicity of the

5 material forming the outer layer, stable oil/water emulsions may be prepared having an
inner phase to outer phase ratio approaching 3:1, without phase inversion, which can be
dispersable in water to form stable organic phase droplets without the need for surfactants,
10 viscosity enhancers or high shear rates.

5 Two solutions are prepared, the first being an aqueous solution of the outer
biomaterial. The second is a solution of the polymer which is used to form the inner layer,
15 in a relatively volatile water-immiscible liquid which is a solvent for the polymer, and a
relatively non-volatile water-immiscible liquid which is a non-solvent for the polymer. The
20 relatively volatile water-immiscible solvent is typically a C5-C7 ester, such as isopropyl
acetate. The relatively non-volatile water-immiscible non-solvent is typically a C6-C20
10 hydrocarbon such as decane, undecane, cyclohexane, cyclooctane and the like. In the
25 second solution containing the polymer for the inner layer, the polymer in water-
immiscible solvents are combined so that the polymer fully dissolves and the two solvents
are miscible with agitation. The polymer solution (organic phase) is slowly added to the
30 biomaterial solution (aqueous phase) to form a liquid foam. Typically about three parts of
15 the organic polymer solution having a concentration of about 0.5 to 10 percent of the
polymer is added to one part of the aqueous biomaterial solution having a concentration of
35 about 1 to 20 percent of the biomaterial. The relative concentrations of the solutions and
the ratio of organic phase to aqueous phase utilized in this step essentially determine the
40 size of the final microbubble and wall thickness. After thorough mixing of the liquid foam,
20 it is dispersed into water and typically warmed to about 30 - 35°C with mild agitation.
45 While not intending to be bound by a particular theory, it is believed that the biomaterial in
the foam disperses into the warm water to stabilize an emulsion of the polymer in the
organic phase encapsulated within a biomaterial envelope. To render the biomaterial
50

5 envelope water insoluble, a cross linking agent, such as glutaraldehyde, is added to the
mixture to react with the biomaterial envelope and render it water insoluble, stabilizing the
outer shell. Other cross-linking agents may be used, including the use of carbodiimide
10 cross-linkers.

5 Since at this point the inner core contains a solution of a polymer, a solvent and a
non-solvent with different volatilities, as the more volatile solvent evaporates, or is diluted,
15 the polymer precipitates in the presence of the less volatile non-solvent. This process
forms a film of precipitate at the interface with the inner surface of the biomaterial shell,
thus forming the inner shell of the microbubble after the more volatile solvent has been
20 reduced in concentration either by dilution, evaporation or the like. The core of the
microbubble then contains predominately the organic non-solvent. The microbubbles may
25 then be isolated by centrifugation, washed, formulated in a buffer system, if desired, and
dried. Typically, drying by lyophilization removes not only the non-solvent liquid core but
also the residual water to yield gas-filled hollow microbubbles.

15 It may be desirable to further modify the surface of the microbubble, for example,
in order to passivate surfaces against macrophages or the reticuloendothelial system (RES)
35 in the liver. This may be accomplished, for example by chemically modifying the surface
of the microbubble to be negatively charged since negatively charged particles appear to
better evade recognition by macrophages and the RES than positively charged particles.

40 20 Also, the hydrophilicity of the surface may be changed by attaching hydrophilic
conjugates, such as polyethylene glycol (PEGylation) or succinic acid (succinylation) to
45 the surface, either alone or in conjunction with the charge modification.

The biomaterial surface may also be modified to provide targeting characteristics
for the microbubble. The surface may be tagged by known methods with antibodies or

biological receptors.

The microbubbles may also be sized or processed after manufacture. This is an advantage over lipid-like microbubbles which may not be subjected to mechanical processing after they are formed due to their fragility.

The final formulation of the microbubbles after preparation, but prior to use, is in the form of a lyophilized cake. The later reconstitution of the microbubbles may be facilitated by lyophilization with bulking agents which provide a cake having a high porosity and surface area. The bulking agents may also increase the drying rate during lyophilization by providing channels for the water and solvent vapor to be removed. This also provides a higher surface area which would assist in the later reconstitution. Typical bulking agents are sugars such as dextrose, mannitol, sorbitol and sucrose, and polymers such as PEG's and PVP's.

It is undesirable for the microbubbles to aggregate, either during formulation or during later reconstitution of the lyophilized material. Aggregation may be minimized by maintaining a pH of at least one to two pH units above or below the isoelectric point(P_i) of the biomaterial forming the outer surface. The charge on the surface is determined by the pH of the formulation medium. Thus, for example, if the surface of the biomaterial has a P_i of 7 and the pH of the formulation medium is below 7, the microbubble will possess a net positive surface charge. Alternatively, if the pH of the formulation medium is greater than 7, the microbubble would possess a negative charge. The maximum potential for aggregation exist when the pH of the formulation medium approaches the P_i of the biomaterial used in the outer shell. Therefore by maintaining a pH of the formulation medium at least one to two units above or below the P_i of the surface, microbubble aggregation will be minimized. As an alternative, the microbubbles may be formulated at

5 or near the P_i with the use of surfactants to stabilize against aggregation. In any event,
buffer systems of the final formulation to be injected into the subject should be
physiologically compatible.

10 The bulking agents utilized during lyophilization of the microbubbles may also be
5 used to control the osmolality of the final formulation for injection. An osmolality other
than physiological osmolality may be desirable during the lyophilization to minimize
15 aggregation. However, when formulating the microbubbles for use, the volume of liquid
used to reconstitute the microbubbles must take this into account.

20 Other additives may be included in order to prevent aggregation or to facilitate
10 dispersion of the microbubbles upon formulation. Surfactants may be used in the
formulation such as poloxomers (polyethylene glycol-polypropylene glycol-polyethylene
25 glycol block co-polymers). Water soluble polymers also may assist in the dispersion of the
microbubbles, such as medium molecular weight polyethyleneglycols and low to medium
molecular weight polyvinylpyrrolidones.

30 15 It will be realized that various modifications of the above-described processes may
be provided without departing from the spirit and scope of the invention. For example, the
35 wall thickness of both the outer and inner layers may be adjusted by varying the
concentration of the components in the microbubble-forming solutions. The mechanical
properties of the microbubbles may be controlled, not only by the total wall thickness and
40 20 thicknesses of the respective layers, but also by selection of materials used in each of the
layers by their modules of elasticity and elongation, molecular-weight, hoop strength, and
45 degree of cross-linking of the layers. Hoop strength being defined as a mechanical
property of a sphere based on the resistance of a section on the sphere to radial force.
Mechanical properties of the layers may also be modified with plasticizers or other

5 additives. Adjustment of the strength of the shell may be modified, for example, by the
internal pressure within the microbubbles. Precise acoustical characteristics of the
microbubble may be achieved by control of the shell mechanical properties, thickness, as
10 well as size distribution. The microbubbles may be ruptured by ultrasonic energy to
5 release gases trapped within the capsule into the blood stream. In particular, by
appropriately adjusting the mechanical properties, the particles may be made to remain
15 stable to threshold diagnostic imaging power, while being rupturable by an increase in
power and/or by being exposed to its resonant frequency. The resonant frequency may be
20 made to be within the range of transmitted frequencies of diagnostic body imaging systems
10 or may be a harmonic or subharmonic of such frequencies. During the formulation process
the microbubbles may be prepared to contain various gases, including blood soluble or
25 blood insoluble gases.

The preferred embodiment is a bi-layered microbubble with a biopolymer outer
30 shell and a synthetic polymer inner layer.

15 Typical diagnostic or therapeutic targets for microbubbles of the invention are the
heart, liver, kidney, vascular system and tumors.

35 The following examples are provided by way of illustration, and are not intended to
limit the invention in any way.

Example 1

40 20 A Hewlett Packard SONOS 2500 ultrasonic scanner was used. This scanner has
the capability of measuring the acoustic density (AD) as a function of time within a region
45 of interest (ROI) displayed on the video monitor. The scanner was set in the 2D harmonic
mode with send frequency of 1.8 MHZ and receive frequency of 3.6 MHZ. A test cell was
constructed comprising a 3.8 mm diameter cellulose tubing (the imaging tube) running
50

5 through a plastic beaker approximately 3 cm below the top. Degassed water was used to
fill the beaker. A flow system was connected to the imaging tube consisting of a mixing
reservoir with microsphere contrast agent suspended in it, a peristaltic pump and a
10 pressure transducer with digital readout. A backpressure valve was placed on the drain
5 end of the tube to be able vary the system pressure. The transducer focus was set on the
center of the imaging tube and the ROI placed within the image of the tubing lumen. The
15 scanner was set in the AD mode and the AD readings were recorded by the scanner. The
system was run with zero back pressure to establish a baseline and then the discharge flow
valve was closed to achieve a desired pressure and the procedure repeated. Pressures
20 were increased to roughly 200 mm Hg and then decreased during the study.

Several different gas containing microbubble agents were employed and all yield a
25 linear relationship as exemplified in Figure 1. Also, several different power values
(mechanical index or "MI") were utilized. In all cases, a linear decrease of AD was
observed as a function of pressure for a fixed MI, thus demonstrating selective fragility.

15 Example 2

Hewlett Packard SONOS 5500 ultrasound scanner was used in conjunction with a
35 an ATS Laboratories, Model 524 Doppler Flow Phantom. The setup was essentially the
same as Example 1. However, the scanner was set up in the Angio (Power Doppler or
Doppler decorrelation) mode. In this mode, decorrelation events as determined by
40 20 Doppler signal processing above a preset threshold are displayed on the monitor of the
ultrasound scanner. The flow phantom consists of a housing filled with an elastomer
45 which is designed to mimic the attenuation of living tissue and has four flow channels of 2,
4, 6, & 8mm diameter respectively running through it. The 6 mm diameter channel of the
flow phantom was chosen. The sector scan transducer was oriented along the centerline

of the flow tube. When operated in the Angio mode and when microbubbles are present in the flow tube of the phantom, a colored plume derived from the decorrelation events is displayed on the monitor. The plume corresponds to the disruption or disintegration of microbubbles within the scanned ultrasound field. All tests were performed with a pulse repetition frequency of 1.2 kHz, an triggering interval of 2000 ms, 8 pulse Doppler packet and various values of TIS (Thermal Index, Soft tissue: a measure of output power) and various formulations microbubbles having an outer layer of albumin and an inner layer of d, l lactide. Using the caliper function of the system, one can measure the distance from the first point of insonation to the end of the plume on the centerline of the channel. Very fragile microbubbles fail instantly as they enter the sound field and the plume is very short, typically only a few millimeters, whereas more durable microbubbles produce a plume which can extend across the image. Since the plume changes with number of decorrelation events, a measure of, agent fragility is accomplished and one can then examine the results under varying ambient pressures. By adjusting the discharge (backpressure) valve, one can take measurements of the plume length with varying pressure. If the microbubbles exhibit engineered fragility properties, the plume length should change under differing pressure conditions which are dependent upon the properties of the microbubbles. Indeed this is the case as exemplified in the Figure 2.

As can be seen in FIG. 2, there is a linear decrease in plume length with pressure with a correlation coefficient of 0.98. This particular test did not require high power levels. The tests were performed under various power conditions ranging from a TIS value of 0.2 to 1.0 and in all cases tested there was a linear relationship between plume length and pressure.

Example 3

5 The set-up as presented in Example 2 above was used with the exception that the
flow phantom was exchanged for a 6.5 cm diameter by 7.6 cm high acrylic cylindrical
phantom chamber with a sealed top and bottom. A magnetic stirring bar was placed in the
10 chamber and the chamber filled completely with de-gassed water. Two ports with lucr
5 lock syringe fittings are present to allow connection to the chamber. One port is
connected to the pressure transducer, and the other port connected through a 3-way valve
15 to a pressurizing syringe and a sample injection syringe. The S4 transducer of the HP
5500 scanner was placed in a water-filled well on the top of the chamber, imaging directly
20 downward through a thin acrylic cover. The HP SONOS 5500 was run in Angio mode
10 and in B-mode Harmonic. The transducer focus was set at 4 cm in depth, near the mid
chamber position. A diluted sample of gas filled, dual walled microbubbles (described in
25 Example 8) was injected into the chamber with the pressure transducer port open to
relieve the pressure build-up from sample introduction. The pressure transducer port was
30 closed and the 3-way valve switched to the pressurizing syringe, which is filled with water.
15 The chamber is placed on a magnetic stirrer set to slow speed.

The ultrasound scanner was turned on and the Power Doppler image displayed is
35 of a somewhat spherical region of signals from Doppler decorrelation events within the
central region of the phantom. The pressurizing syringe is then engaged to bring the
pressure up to approximately 150 to 200 mm Hg and back to ambient at approximately 30
40 cycles per minute. The display shows the region of decorrelation signals diminishing in
20 size significantly with the increase in pressure and returning to baseline as the pressure
returns to ambient. The image changes indicate the correspondence of the Doppler
45 decorrelation signals to the ambient pressure. The results were recorded to videotape.

Example 4

5 Using the set-up with the HP SONOS 5500 and Doppler Flow Phantom as detailed
in Example 2 above, a test was performed to determine the variations in fragility
thresholds and their relationship to ambient pressure of microbubbles fabricated with
10 differing wall thickness. Three samples of microbubbles (described in Example 8) were
5 fabricated with polylactide inner walls of thickness approximately 28, 55 and 110nm
respectively. The samples were interrogated using B-mode Harmonic imaging at 1.8 MHz
15 send and 3.6 MHz receive frequencies. Using the AD function, an ROI was placed at the
input end of the image of the flow channel and densitometry readings taken at each
increment. The ROI was moved laterally, in increments along the flow direction and
20 readings taken. The resultant graph, Figure 3, shows the exemplary results for one sample
(55nm thickness) as a function of mean AD value versus distance in centimeters along the
25 flow channel. The slope of this line is called the Fragility Slope (FS). The results from all
samples indicate a linear decrease in backscattered signal with distance from the source,
and exposure to the ultrasound field.

30 15 The test is repeated at MI values from 0.0 to 1.6, in increments of 0.1 MI. The
slopes of the resultant measurements are then plotted versus the power or MI value, as
35 shown in Figure 4. This curve is termed the Fragility Curve (FC). All three samples show
a region at low power levels where the slopes are essentially zero, then a power level
where the decrease in signal from the destruction of microcapsules begins. Determining
40 20 the curve intercepts with the zero slope value as shown in Figure 5, yields fragility
threshold values for the various samples.

45 Values of AD vs Distance (Figure 3) were determined at ambient and at
approximately 100 and 200 mm Hg respectively. The y-intercept of Figure 3 was taken as
an indication of peak backscatter signal. The peak AD backscatter signal was then plotted
50

5 versus MI at the three test pressures in Figure 6. The curves are roughly equal indicating
that the agent is stable under the test pressures examined and exhibits the same acoustic
behavior at each pressure, and furthermore that agent concentrations in each test were
10 comparable.

5 Fragility Slopes and resultant Fragility Curves for the 110nm wall thickness sample
where generated at different pressures as above. Taking the data in the high MI region,
15 from 1.0 to 1.6, wherein the behavior of the Fragility Curve is nearly linear, three distinct
linear results are seen as in Figure 7. The intercept of these lines with the zero slope value
20 is shown in Figure 8. These curves may be used to compute the ambient pressure of the
10 fluid.

Example 5

Preparation of gelatin polycaprolactone microbubbles

25 A solution of 1.0 gms gelatin (275 bl, isoelectric point of 4.89) dissolved in 20 ml
deionized water was prepared at approximately 60 C. Native pH of the solution was 5.07.
30 Separately, 1.0 gms polycaprolactone (M.W. 50,000) and 6.75 ml cyclooctane was
15 dissolved in 42 ml isopropyl acetate with stirring at approximately 70 C. After cooling to
37 C, the organic mixture was then slowly incorporated into the gelatin solution
35 maintained at 30 C and under moderate shear mixing using a rotary mixer. Once the
organic phase was fully incorporated, the mixing rate was increased to 2,500 rpm for 5
40 minutes and then stirred at low shear for an additional 5 minutes. The resulting o-w
20 emulsion was then added with stirring to 350 ml deionized water maintained at 30 C and
45 containing 1.2 ml 25% glutaraldehyde. Immediately after the addition of the emulsion, the
bath pH was adjusted to 4.7. After 30 minutes, the pH was adjusted to 8.3. Low shear
mixing was continued for approximately 2 ½ hours until the isopropyl acetate had
50

5 completely volatilized. Polyoxamer 188 in the amount of 0.75 gm was then dissolved into
the bath. The resulting microbubbles were retrieved by centrifugation and washed 2 times
in an aqueous solution of 0.25% polyoxamer 188.

10 Microscopic inspection of the microbubbles revealed spherical capsules having a
5 thin-walled polymer shell encapsulating a liquid organic core. Staining the slide
preparation with coomassie blue G indicated the presence of an outer protein layer
15 uniformly surrounding the polymer shell.

The particle size spectrum was determined using a Malvern Micro. Median
20 diameter was 4.78 microns with a spectrum span of 0.94.

10 Example 6

Preparation of microbubble agent formulation

25 A quantity of microbubbles prepared in a manner similar to example 5 were
suspended into an aqueous solution of 25mM glycine, 0.5% pluronic f-127, 1.0% sucrose,
30 3.0% mannitol, and 5.0% PEG-3400. The suspension was then lyophilized. The resulting
15 dry powder was reconstituted in deionized water and examined under the microscope to
reveal that the microbubbles now contained a gaseous core. Staining the preparation with
35 coomassie blue G confirmed that the outer protein layer surrounding the capsules was
intact and had survived the lyophilization process.

40 Echogenicity was confirmed by insonating at both 2 ½ and 5 MHZ a quantity of
20 lyophilized microbubbles dispersed in 120 ml deionized water. Measurement was taken at
•least 15 minutes after dispersion of the microbubbles to insure that the back scattered
45 signal was due solely from the gas contained within the microbubbles. The B mode
display showed a high contrast indicating that the microbubbles were gas filled.

Example 7Preparation of albumin polycaprolactone microbubbles

A 6% aqueous solution was prepared from a 25% solution of USP grade human serum albumin (Alpha Therapeutic Corp) by dilution with deionized water. The solution was adjusted to a pH of 3.49 using 1 N HCl. Separately, 8 parts by weight polycaprolactone (M.W. 50,000) and 45 parts cyclooctane were dissolved in 300 parts isopropyl acetate at approximately 70°C. Once dissolution was complete, the organic solution was allowed to cool to 37°C. With mild stirring, 42.5 gm of the prepared organic solution was slowly incorporated into 25.0 gm of the albumin solution while the mixture was maintained at 30°C. The resulting coarse o-w emulsion was then circulated through a stainless steel sintered metal filter element having a nominal pore size of 7 microns. Recirculation of the emulsion was continued for 8 minutes. The emulsion was then added with stirring to 350 ml deionized water maintained at 30°C and containing 1.0 ml of 25% gluteraldehyde. During the addition, the pH of the bath was monitored to insure that it remained between 7 and 8. Final pH was 7.1. Low shear mixing was continued for approximately 2 ½ hours until the isopropyl acetate had completely volatilized. Poloxamer 188 in the amount of 0.75 gm was then dissolved into the bath. The resulting microbubbles were retrieved by centrifugation and washed 2 times in an aqueous solution of 0.25% poloxamer.

Microscopic inspection of the suspension revealed spherical particles having a thin-walled polymer shell with an outer protein layer and an organic liquid core. The peak diameter as, determined by the Malvern Micro particle size analyzer, was 4.12 microns.

The suspension was then lyophilized in a manner similar to that described in Example 6. The resulting dry cake was reconstituted with deionized water and examined

under the microscope to reveal that the microbubbles were spherical, discrete, and contained a gaseous core.

Example 8

Preparation of albumin polylactide microbubbles

A 6% aqueous solution was prepared from a 25% solution of USP grade human albumin by dilution with deionized water. Ion exchange resin (AG 501-X8, BioRad Laboratories) was then added to the solution at a ratio of 1.5 gm resin to 1.0 gm dry weight of albumin. After 3 hours the resin was removed by filtration and the pH of the solution was adjusted from 4.65 to 5.5. Separately, 0.41 gm d-l lactide (0.69 dL/gm in CHCl_3 at 30°C) and 5.63 gm cyclooctane were dissolved in 37.5 gm isopropyl acetate. The organic solution was then slowly incorporated into 25.0 gm of the prepared albumin solution with mild stirring while the mixture was maintained at 30°C. The resulting coarse o/w emulsion was then circulated through a stainless steel sintered metal filter element having a nominal pore size of 7 microns. Recirculation of the emulsion was continued for 8 minutes. The emulsion was then added with stirring to 350 ml deionized water maintained at 30°C and containing 1.0 ml of 25% glutaraldehyde. During the addition, the pH of the bath was monitored to insure that it remained between 7 and 8. Final pH was 7.0. Low shear mixing was continued for approximately 2½ hours until the isopropyl acetate had completely volatilized. Polyoxamer 188 in the amount of 0.75 gm was then dissolved into the bath. The resulting microbubbles were retrieved by centrifugation and washed 2 times in an aqueous solution of 0.25% polyoxamer.

Microscopic inspection revealed hollow spherical polymer microbubbles having an outer protein layer and an inner organic liquid core. The suspension was formulated with a glycine/PEG 3350 excipient solution, then lyophilized. The resulting dry cake was

5 reconstituted with deionized water and examined under the microscope to reveal that the
microbubbles were spherical, discrete, and contained a gaseous core.

Example 9

PEG modification of the microbubble surface

10
5 Microbubbles were prepared in a manner similar to Example 7. After
centrifugation, 4 ml of the microbubbles containing cream (approximately 11 ml total
15 yield) was resuspended in 31 ml deionized water. To this was added a 10 ml solution
containing 0.3 gm methoxy-peg-NCO 5000 and the pH was adjusted to 8.7. The mixture
20 was allowed to react at room temperature with mild agitation for 4½ hours. At the end of
this period the pH was measured to be 7.9. The microbubbles were retrieved by
10 centrifugation and washed 2 times in a 0.25% solution of polyoxamer 188. The
25 suspension was formulated with a glycine/PEG 3350 excipient solution, then lyophilized.
The resulting dry cake was reconstituted with deionized water and examined under the
30 microscope to reveal that the microbubbles were spherical, discrete, and contained a
15 gaseous core.

Example 10

Preparation of wall modified albumin polycaprolactone microbubbles

35 Albumin coated microbubbles were prepared in a manner similar to Example 7 with
the exception that 0.20 gm paraffin was also dissolved into the organic solution along with
40 the polycaprolactone and the cyclooctane.
20

45 Microscopic inspection of the finished microbubble suspension revealed spherical
particles having a morphology and appearance virtually identical to those prepared without
the addition of paraffin.

Example 11

5

10

5

15

20

10

25

30

35

40

45

50

55

During a patient examination, the physician injects a bolus of microbubble pressure agent intravenously. Using the ultrasound scanner, the physician images the chambers of the heart, primarily the left ventricle. With the scanner focused within the left ventricle and electrocardiogram (ECG) leads attached to the patient, the physician sets the scanner in Power Doppler (Doppler Decorrelation) mode. The ultrasound scanner is set-up to trigger based on ECG input, with the trigger point near to or at the end of diastolic cycle. The intensity of the image is correlation to the ambient pressure by way of a predetermined response of the microbubble agent. The resultant image intensity, when compared to the predetermined response, yields the end diastolic left ventricular pressure. This information is especially useful in determine cardiac ejection fraction which is a measure of the output of the heart.

WHAT IS CLAIMED IS:

1. A method for measuring real time pressure at a region of interest in a fluid-filled body cavity comprising the steps of:

(a) introducing into said cavity a composition of gas-containing microbubbles, said microbubbles having a predetermined fragility threshold, said fragility threshold correlating the rupture response of their capsule to fluid pressure, applied acoustic pressure, or a combination of fluid and applied acoustic pressures, said acoustic pressure being applied from an ultrasonic energy producing source and said microbubble composition having predetermined acoustic response properties correlating to ambient pressure of a surrounding fluid;

(b) applying an ultrasonic signal at said region of interest at a power level sufficient to cause acoustic pressure sufficient to destroy the microbubble population having a fragility threshold below said power level;

(c) detecting the returned acoustic signals backscattered from the population of disintegrating and intact microbubbles remaining at said region of interest;

(d) correlating said returned acoustic signals to said predetermined acoustic response properties of said microbubble composition to determine said ambient pressure at said region of interest.

2. A method according to claim 1 further comprising the steps of displaying said correlation on a monitor of an ultrasound scanner.

3. A method according to claim 1 wherein said composition comprises of one or more layers.

- 5 4. A method according to claim 1 wherein said microbubbles contain a
physiologically acceptable gas.
5. A method according to claim 4 wherein said gas is nitrogen.
- 10 6. A method according to claim 4 wherein said gas is air.
7. A method according to claim 4 wherein said gas is a fluorocarbon
15 compound.
8. A method according to claim 1 wherein said composition is introduced into
said cavity as a bolus.
- 20 9. A method according to claim 1 wherein said composition is introduced to
10 said cavity as a controlled rate infusion.
10. A method according to claim 1 wherein the fragility threshold of said
25 microbubbles is controlled by selecting the thickness of one or more walls of the capsule.
11. A method according to claim 1 wherein the fragility threshold of said
30 microbubbles is controlled through use of materials of differing moduli of elasticity.
12. A method according to claim 1 wherein the fragility threshold of said
15 microbubbles is controlled through use of materials of differing molecular weight.
13. A method according to claim 1 wherein the fragility threshold of said
35 microbubbles is controlled through use of materials of differing hoop strength.
14. A method according to claim 1 wherein the rupture response of said
40 microbubbles approximates a step function at one or more pressure levels.
- 20 15. A method according to claim 1 wherein the rupture response is a linear
45 relationship with ambient pressure in combination with constant ultrasound pressure.
16. A method according to claim 1 wherein said step of applying an ultrasonic
50 signal and said step of detection are accomplished with an ultrasound imaging system.

5 17. A method according to claim 16 wherein the response of said microbubbles
is detected utilizing B-mode harmonic imaging methods.

10 18. A method according to claim 16 wherein the response of said microbubbles
is detected utilizing power Doppler decorrelation imaging methods.

15 19. A method according to claim 18 wherein the ambient fluid pressure is
determined by comparing the quantity or intensity of decorrelation events and the known
response of said microbubbles.

20 20. A method according to claim 19 wherein the resultant ambient fluid
pressure measurement is displayed on a monitor of an ultrasound scanner.

25 21. A method according to claim 19 wherein the results are displayed in real
time.

30 22. A method according to claim 19 wherein the results are displayed as a
greyscale map of ambient pressure.

35 23. A method according to claim 19 wherein the results are displayed as a
greyscale map of ambient pressure.

40 24. A method according to claim 19 wherein the results are displayed as a color
map of ambient pressure.

45 25. A method according to claim 19 wherein the results are displayed as a map
correlating to the electrocardiogram of the subject to display pressure as a function of time
point within the cardiac cycle.

50 26. A method according to claim 23 wherein the colors of the color map are
coded to the amplitude of the ambient pressure.

55 27. A method according to claim 1 wherein said composition comprises two or
more population of microbubbles of differing fragility thresholds.

5 28. A method according to claim 1 wherein the response of said microbubbles
is detected by way of interrogation with an ultrasound signal containing capsules of a first
low power signal to establish a baseline and a second higher power signal to destroy the
10 microbubble population whose fragility threshold is below said second power level and
5 with a subsequent third high power signal to measure the resultant signal.

15 29. A method according to claim 27 wherein the ultrasound signal comprises a
single pulse train wherein the two differing power levels are produced such that a first low
power pulse is sent at the beginning of said pulse train and second and third high power
20 pulses at the middle and the end of said pulse train, respectively.

10 30. A method according to claim 27 wherein the ultrasound signal comprises
two or more pulse trains wherein the first pulse train is of low power and subsequent pulse
25 trains are of higher power.

30 31. A method according to claim 27 wherein the ultrasound signal comprises
15 three or more pulse trains wherein the first pulse train is of low power and each
subsequent pulse train is of consecutively higher power than the previous pulse train.

35 32. A method according to claim 27 wherein the backscatter intensity from said
microbubbles from the first low power signal is recorded as a baseline value.
40 20

45 33. A method according to claim 27 wherein the second high power signal is at
a power level above the fragility threshold of one or more populations of said composition.

50 34. A method according to claim 31 wherein the backscatter intensity from the

5 third high power signal is subtracted from said baseline to yield a difference value.

10 35. A method according to claim 33 wherein the difference value is compared
to experimental reference values to measure ambient fluid pressure.

15 36. A method according to claim 34 wherein the ambient fluid pressure
measurement is displayed on the screen of an ultrasound scanner associated with the
defined region of interest.

20 37. A method of determining the fragility thresholds of a plurality of
populations of microbubbles and correlating said thresholds to ambient pressures at
25 rupture surrounding said microbubbles comprising the steps of:

30 a) determining the fragility slope of each said populations from
respective curves, said curves determined by measuring acoustic density as each of said
15 population as it is acoustically interrogated along a channel versus distance along said
channel;

35 b) determining fragility curves by plotting each of said fragility slopes
versus mechanical index, a measure of the acoustic power used to interrogate said
populations;

40 c) identifying the intercept of substantially linear portions of each of
20 said fragility curves at zero fragility slope as the mechanical index at the threshold fragility
for said population;

45 d) correlating each of said mechanical indices at the threshold fragility
to an ambient pressure from a predetermined mechanical index-to-pressure relationship.

5

38. The method according to claim 36 wherein said fragility slopes are determined for a plurality of populations of microbubbles having differing wall thickness.

10

5

39. The method according to claim 36 wherein said fragility slopes are determined for a plurality of populations of microbubbles having differing moduli of elasticity.

15

20

10

40. The method according to claim 36 wherein said fragility slopes are determined for a plurality of populations of microbubbles having materials of differing molecular weight.

25

30

15

41. The method according to claim 36 wherein said fragility slopes are determined for a plurality of populations of microbubbles having materials of differing hoop strength.

35

42. The method according to claim 36 wherein said fragility curves are determined for a plurality of populations of microbubbles having differing wall thickness.

40

20

43. The method according to claim 36 wherein said fragility curves are determined for a plurality of populations of microbubbles having differing moduli of elasticity.

45

50

44. The method according to claim 36 wherein said fragility curves are determined for a plurality of populations of microbubbles having materials of differing

55

5 molecular weight.

10 45. The method according to claim 36 wherein said fragility curves are
determined for a plurality of populations of microbubbles having materials of differing
5 hoop strength.

15

20

25

30

35

40


45

50


35

55


1/6

Figure 1



2/6

Figure 2


3/6

Figure 3



4/6

Figure 4Figure 5

5/6

Figure 6

6/6

Figure 7Figure 8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/08259

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61B 8/00 US CL : 600/438 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 600/437, 438, 442, 455-458, 485-486 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) NONE														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
A	US 4,483,345 A (MIWA) 20 November 1984, col. 1 lines 41-51.	1												
A,P	US 5,971,928 A (DODD et al.) 26 October 1999, col. 6 lines 50-55	1												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"><tr><td>* Special categories of cited documents:</td><td>*T* later documents published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*A* document defining the general state of the art which is not considered to be of particular relevance</td><td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*B* earlier document published on or after the international filing date</td><td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*A* document member of the same patent family</td></tr><tr><td>*O* document referring to an oral disclosure, use, exhibition or other means</td><td></td></tr><tr><td>*P* document published prior to the international filing date but later than the priority date claimed</td><td></td></tr></table>			* Special categories of cited documents:	*T* later documents published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later documents published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family													
O document referring to an oral disclosure, use, exhibition or other means														
P document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 02 JUNE 2000		Date of mailing of the international search report 13 JUL 2000												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer FRANCIS J. JAWORSKI Telephone No. (703) 308-3061												